[go: up one dir, main page]

IN2009CN03372A - - Google Patents

Download PDF

Info

Publication number
IN2009CN03372A
IN2009CN03372A IN3372CHN2009A IN2009CN03372A IN 2009CN03372 A IN2009CN03372 A IN 2009CN03372A IN 3372CHN2009 A IN3372CHN2009 A IN 3372CHN2009A IN 2009CN03372 A IN2009CN03372 A IN 2009CN03372A
Authority
IN
India
Prior art keywords
protein
canine
tslp
peptide fragments
canine tslp
Prior art date
Application number
Inventor
Jeanine D Mattson
Daniel M Gorman
Waal Malefyt Rene De
Mohamad A Morsey
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of IN2009CN03372A publication Critical patent/IN2009CN03372A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/43—Sweetening agents, e.g. thaumatin, monellin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5418—IL-7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/202—Dermatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Botany (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Abstract CANINE THYMIC STROMAL LYMPHOPOIETIN PROTEIN AND USES THEREOF The present invention discloses a canine TSLP protein and a nucleic acid that encodes that protein. Peptide fragments of the protein that comprise specific epitopes of the canine TSLP protein are also disclosed. The canine TSLP protein and related peptide fragments may be used as an antigen for immunological as well as for vaccines that induce anti-TSLP antibodies. The present further discloses methods of making and using the canine TSLP gene, the canine TSLP protein, and the related peptide fragments.
IN3372CHN2009 2006-12-14 2007-12-11 IN2009CN03372A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87513506P 2006-12-14 2006-12-14
PCT/US2007/025318 WO2008076255A2 (en) 2006-12-14 2007-12-11 Canine thymic stromal lymphopoietin protein and uses thereof

Publications (1)

Publication Number Publication Date
IN2009CN03372A true IN2009CN03372A (en) 2015-08-07

Family

ID=39430681

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3372CHN2009 IN2009CN03372A (en) 2006-12-14 2007-12-11

Country Status (18)

Country Link
US (3) US7718772B2 (en)
EP (1) EP2104683B1 (en)
JP (4) JP2010512744A (en)
KR (1) KR101525631B1 (en)
CN (2) CN101631800B (en)
AU (1) AU2007334531B2 (en)
BR (1) BRPI0720001A2 (en)
CA (1) CA2671865C (en)
CO (1) CO6210756A2 (en)
ES (1) ES2582655T3 (en)
IL (2) IL199170A (en)
IN (1) IN2009CN03372A (en)
MX (1) MX2009006470A (en)
NZ (1) NZ578352A (en)
RU (2) RU2457217C2 (en)
UA (3) UA95329C2 (en)
WO (1) WO2008076255A2 (en)
ZA (1) ZA200904152B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2582655T3 (en) * 2006-12-14 2016-09-14 Intervet International Bv Canine thymic stromal lymphopoietin protein and uses thereof
JP5492158B2 (en) 2011-08-24 2014-05-14 富士フイルム株式会社 Antibodies against human TSH and dog TSH
WO2013119419A1 (en) 2012-02-08 2013-08-15 North Carolina State University Treatment of allergic diseases with recombinant antibodies
AR090915A1 (en) 2012-05-04 2014-12-17 Intervet Int Bv PROTEIN OF FUSION OF PROTEIN LINFOPOYETINA ESTROMAL TIMICA CANINA WITH THE REGION FC OF IGG
US20160052985A1 (en) * 2013-04-04 2016-02-25 Ieo - Istituto Europeo Di Oncologia Srl Thymic stromal lymphopoietin fragments and uses thereof
ES2730978T3 (en) * 2013-08-09 2019-11-13 Astellas Pharma Inc New human TSLP anti-receptor antibody
EP4566623A3 (en) 2013-12-20 2025-08-20 Intervet International B.V. Caninized antibodies
WO2015118124A1 (en) * 2014-02-06 2015-08-13 Vib Vzw Thymic stromal lymphopoietin receptor antagonist
CN107683291B (en) 2015-04-02 2021-11-19 英特维特国际股份有限公司 Antibodies to canine interleukin-4 receptor alpha
WO2017042701A1 (en) 2015-09-09 2017-03-16 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
EP3347377B1 (en) 2015-09-09 2021-02-17 Novartis AG Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
EP4541807A3 (en) 2015-12-18 2025-09-24 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
JP7127859B2 (en) 2016-11-09 2022-08-30 ノース カロライナ ステート ユニバーシティ Treatment of allergic diseases using chimeric proteins
WO2019183437A1 (en) 2018-03-23 2019-09-26 North Carolina State University Methods and compositions for antibody to high affinity receptor for ige
CN115028722B (en) * 2021-03-05 2024-09-03 拜西欧斯（北京）生物技术有限公司 Anti-TSLP antibodies, methods of making and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
ZA887773B (en) 1987-10-26 1989-07-26 Immunex Corp Interleukin-7
US5714585A (en) 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US6844170B1 (en) 1998-03-19 2005-01-18 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US20030099947A1 (en) 1998-09-21 2003-05-29 Bazan J. Fernando Mammalian cytokines; related reagents and methods
ES2288036T5 (en) * 1998-11-13 2017-07-06 Immunex Corporation Human TSLP DNA and polypeptides
AU2396600A (en) 1998-12-30 2000-07-31 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
GB9908533D0 (en) * 1999-04-14 1999-06-09 Novartis Ag Organic compounds
US7964713B2 (en) 2000-06-28 2011-06-21 Amgen Inc. Nucleic acid molecules encoding thymic stromal lympopoietin receptor proteins and a process for producing the encoded polypeptides thereof
US6890734B2 (en) 2000-11-10 2005-05-10 Schering Corporation Nucleic acids encoding a cytokine receptor complex
AU2004257781B2 (en) * 2003-07-18 2009-07-16 Merck Sharp & Dohme Corp. Treatment and diagnosis of neoplasms using Thymic Stromal Lymphopoietin
WO2006023226A2 (en) * 2004-07-28 2006-03-02 Tanox, Inc. Thymic stromal lymphopoietin promoter and uses therefor
SE532251C2 (en) 2006-11-28 2009-11-24 Theravac Pharmaceuticals Ab New formulations of TSLP for the treatment of TH2-mediated inflammatory diseases by vaccination
ES2582655T3 (en) 2006-12-14 2016-09-14 Intervet International Bv Canine thymic stromal lymphopoietin protein and uses thereof

Also Published As

Publication number Publication date
CN102584998B (en) 2017-07-04
KR20090097921A (en) 2009-09-16
US8791242B2 (en) 2014-07-29
CN101631800A (en) 2010-01-20
AU2007334531A1 (en) 2008-06-26
US7718772B2 (en) 2010-05-18
JP2013048637A (en) 2013-03-14
RU2457217C2 (en) 2012-07-27
CN101631800B (en) 2012-12-05
JP2010512744A (en) 2010-04-30
AU2007334531B2 (en) 2012-04-12
NZ578352A (en) 2012-05-25
EP2104683A2 (en) 2009-09-30
JP6117767B2 (en) 2017-04-19
JP5707380B2 (en) 2015-04-30
IL215507A0 (en) 2011-11-30
US20130183291A1 (en) 2013-07-18
CA2671865C (en) 2017-01-10
ES2582655T3 (en) 2016-09-14
JP2015107121A (en) 2015-06-11
WO2008076255A3 (en) 2008-09-18
US8076456B2 (en) 2011-12-13
UA120027C2 (en) 2019-09-25
BRPI0720001A2 (en) 2013-12-24
KR101525631B1 (en) 2015-06-04
RU2009126617A (en) 2011-01-20
IL199170A (en) 2015-04-30
EP2104683B1 (en) 2016-05-25
UA95329C2 (en) 2011-07-25
CN102584998A (en) 2012-07-18
ZA200904152B (en) 2011-11-30
RU2012113162A (en) 2013-10-20
US20110033478A1 (en) 2011-02-10
CO6210756A2 (en) 2010-10-20
JP2012090647A (en) 2012-05-17
WO2008076255A2 (en) 2008-06-26
RU2617957C2 (en) 2017-04-28
MX2009006470A (en) 2009-06-26
CA2671865A1 (en) 2008-06-26
UA108064C2 (en) 2015-03-25
US20080152620A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
IN2009CN03372A (en)
JO3351B1 (en) Antigen binding proteins capable of binding thymic stromal lymphopoietin
MX2009012812A (en) Mutated parvovirus structural proteins as vaccines.
WO2011032161A3 (en) Vaccines directed to langerhans cells
MY162752A (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
WO2007106476A3 (en) Compositions and methods for enhancing the immunogenicity of antigens
NZ577828A (en) Human antibodies that bind human il-12 and methods for producing
WO2010104747A3 (en) Antigen presenting cell targeted vaccines
WO2010104761A3 (en) Anti-cd40 antibodies and uses thereof
NZ600584A (en) Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof
CU20120095A7 (en) PCSK9 ANTAGONISTS
UA93855C2 (en) Neutralizing epitope-based growth enhancing vaccine
WO2008005880A3 (en) Antibodies for norovirus
MX2011012039A (en) Blocking anti-dkk-1 antibodies and their uses.
MX2009013824A (en) Antigen binding proteins that bind par-2.
WO2008130382A3 (en) Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
WO2006124451A3 (en) Anti-il-13 antibodies, compositions, methods and uses
WO2007050095A3 (en) Improved vaccines and methods for using the same
WO2007127372A3 (en) Genetic adjuvants for viral vaccines
MX2009008754A (en) Novel antibodies against igf-ir.
UA100531C2 (en) Antigen binding proteins capable of binding thymic stromal lymphopoietin
MX2009011851A (en) Dna plasmids having improved expression and stability.
AU2005292852A8 (en) Method of immunizing animal, composition for immunization, method of producing antibody, method of producing hybridoma and method of producing monoclonal antibody
WO2007020520A3 (en) Antigenic peptides and their use
DE602005010680D1 (en) COMPOSITIONS AND METHOD FOR INDUCING AN ANTITUMORIMMUNITY